Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
The portal centralizes messaging, shipping status, and refills
Source: Jastreboff et al., NEJM 2023 TRIUMPH-4 Phase 3 (68 weeks, 445 participants) Phase 2 Type 2 Diabetes Trial (36 weeks, 281 participants) In the type 2 diabetes population, weight loss was lower than in the obesity trial which is consistent with the pattern seen across all GLP-1 drugs
the latter classified by Statistics Denmark according to the so-called SOCIO13 classification ) were identified on the year preceding each individuals index year
Persistent hunger often signals a metabolic imbalance that requires attention
Tirzepatide also reduces liver fat, with estimates around 50-60% from available data